SUNNYVALE, California,
October 19, 2017 /PRNewswire/ --
Accuray Incorporated (NASDAQ: ARAY)
announced today that the Court of Appeal of Nantes has rejected the
appeal filed by Varian Medical Systems opposing the purchase of the
Accuray TomoTherapy® System by University Hospital of Tours (CHU).
This most recent legal ruling marks the final appeal by Varian in
their efforts to overturn CHU's tender award and block their use of
the TomoTherapy technology. CHU is the first public hospital in the
Centre-Val de Loire region and the first hospital in France to install both the TomoTherapy and
CyberKnife® Systems.
"We are extremely pleased by the court's verdict which
reinforces a clinical team's right to select the radiation therapy
system they feel best meets the needs of their facility, team and
patients," said Lionel Hadjadjeba, MD, Senior Vice President and
Chief Commercial Officer at Accuray. "CHU Tours' decision to
purchase a TomoTherapy System reflects our system's ability to
deliver precise radiation treatments like no other system in the
world. We're committed to supporting the CHU clinical team, and all
of our customers, to improve treatment and quality of life for
their patients."
The Court of Appeal has confirmed the CHU Tours decision on all
points, concluding that:
- The tender award in favor of TomoTherapy Europe should not be
cancelled;
- The medical needs expressed by CHU Tours were well-defined in
the administrative documents of the tender;
- The TomoTherapy System is the only radiation therapy device
which provides continuous helical delivery of radiation from 360
degrees around the patient, a unique method for delivering
image-guided IMRT which enables clinicians to modulate the dose in
an optimal way and to irradiate large fields without repositioning
the patient;
- This technique is expressly recommended by the French National
Authority for Health (HAS) for craniospinal irradiations, often
used in pediatric tumors, and for total body irradiation in the
treatment of blood tumors.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The Company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 25,
2017, and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.